Exclusives

A recent evaluation confirmed that the use of an AI-based Smart Diabetic Foot Ulcer Scoring System is a valuable diagnostic tool for healthcare professionals and can significantly improve the care standards in the field of diabetic foot ulcer...

A 20-patient study found a combination of limited debridement and application of ReCell for treatment of second-degree burns was effective with short healing time, mild scar formation and little damage to the donor skin area. J Plastic Surg

Legacy Medical Consultants is initiating a 120-patient interventional study comparing SOC to Orion TM Amniotic Membrane for the treatment of DFUs. The primary outcome measure is incidence of complete wound closure at 12 weeks. The estimated...

PolarityTE announced the company has secured $22.5MM in financing to advance SkinTE Phase III Pivotal Study in DFUs. COVER DFUS II will enroll up to 120 patients at up to 20 clinical sites in the US. The primary endpoint is percent DFUs...

Kerecis presented data from the ODIN RCT, an EU multicenter trial for UT Grade 2 and 3 DFUs. The 255-patient trial compared FSG to SOC with the primary endpoint percent closure at 16 weeks. Healing in the FSG group was 44% at 16 weeks and 26%...

BSEM believes the proposed LCDs would severely limit patient access to well-established products and noted that currently 60% to 80% of the private office volume is on the non-covered list. BSEM Q124 Earnings Transcript on Seeking Alpha

SMTI provided an update on its partnership with InfuSystem, which is focused on 3 potential areas of opportunity: distribute SMTI's AWC products, including BIAKŌS and HYCOL, as well as NPWT, into LTC, SNF and wound centers. SMTI Q124 Earnings...

SNN displayed their new NPWT product, Renasys Edge, at the innovation theater section of SAWC. This mini reusable NPWT device is designed for portability and intended for use outside the hospital setting and can be obtained from their partner...

The nitric oxide technology platform is moving forward in Europe and the US with plans to file the regulatory approvals during the course of 6 to 12 months. It anticipates introducing the nitric oxide technology platform in the 2025/26 time...